Sign up for our complimentary
weekly e-journal

Main Newsletter
Mastery Series
Therapy Series
 
Bookmark and Share | Print Article | Items for the Week Previous | All Articles This Week | Next
This article originally posted and appeared in  CardiovascularObesityGLP-1Issue 731GLP-1 Special Editions June 2014GLP-1 Special Editions Summer 2014

Reduced Systolic Blood Pressure Observed with Liraglutide

The reduced SBP was also weakly correlated with weight loss....

Advertisement

The study was done to quantify the effect of liraglutide on systolic blood pressure (SBP) and pulse in patients with type 2 diabetes (T2D), and assess the influence of covariates on observed SBP reductions, and was set up as a patient-level pooled analysis of six phase 3, randomized trial.

The results included 2792 randomized patients. In the intention-to-treat population (n=2783), mean [±SE] SBP reductions from baseline with liraglutide 1.2mg (2.7 [0.8] mmHg) and 1.8mg (2.9 [0.7] mmHg) once daily were significantly greater than with placebo (0.5 [0.9] mmHg; P=0.0029 and P=0.0004, respectively) after 26 weeks, and were evident after 2 weeks. Liraglutide was also associated with significantly greater SBP reductions than glimepiride and, at a dose of 1.8mg, insulin glargine and rosiglitazone. SBP reductions with liraglutide weakly correlated with weight loss (Pearson's correlation coefficient: 0.08-0.12; P≤0.0148). No dependence of these reductions on concomitant antihypertensive medications was detected (P=0.1304). Liraglutide 1.2 and 1.8mg were associated with mean increases in pulse of 3 beats per minute (bpm), versus a 1bpm increase with placebo (P<0.0001 for each dose versus placebo).

From the results it was concluded that, liraglutide reduces SBP in patients with T2D, including those receiving concomitant antihypertensive medication.

Practice Pearls:
  • Liraglutide once daily was associated with significant reductions in systolic blood pressure after 26 weeks compared with placebo, with decreases appearing as early as 2 weeks.
  • Reduced systolic blood pressure observed with liraglutide was weakly correlated with weight loss
  • Use of liraglutide may help lower cardiovascular risk in the setting of T2DM.

Reductions in Systolic Blood Pressure With Liraglutide in Patients With Type 2 Diabetes: Insights From a Patient-Level Pooled Analysis of Six Randomized Clinical Trials. J. Diabetes Complicat. 2014 May 01;28(3)399-405, VA Fonseca, JH Devries, RR Henry, M Donsmark, HF Thomsen, J Plutzky 

Advertisement


 

Bookmark and Share | Print | Category | Home

This article originally posted 29 May, 2014 and appeared in  CardiovascularObesityGLP-1Issue 731GLP-1 Special Editions June 2014GLP-1 Special Editions Summer 2014

Past five issues: Diabetes Clinical Mastery Series Issue 247 | Issue 787 | Diabetes Clinical Mastery Series Issue 246 | SGLT-2 Inhibitors Special Edition June 2015 | Issue 786 |

2015 Most Popular Articles:

Triple Therapy Improves Glycemia in Type 1 Diabetes
Posted June 19, 2015
A Dual SGLT1/SGLT2 Inhibitor Can be a Treatment Option in Type 1 Diabetics
Posted June 12, 2015
Canagliflozin and Its Effects on Weight Loss and BP
Posted June 12, 2015
High Fiber Diets Reduce Risk of Diabetes
Posted June 04, 2015
Skin Bacteria a Cause of Diabetes?
Posted June 12, 2015
Efficacy and Safety of an SGLT-2 Inhibitor with Insulin for Type 2s
Posted May 28, 2015
Blood Biomarkers May Predict Risk of Severe Hypoglycemia
Posted June 12, 2015
Lilly Insulin: A Better Alternative than Lantus?
Posted June 19, 2015
Tight Blood Glucose Control and Cardiovascular Disease
Posted June 12, 2015
Are Postprandial Levels in T1 Patients Impacted by More Than Carbohydrates?
Posted May 28, 2015


Browse by Feature Writer & Article Category.
A. Lee Dellon, MD | Aaron I. Vinik, MD, PhD, FCP, MACP | Beverly Price | Charles W Martin, DD | Derek Lowe, PhD | Dr. Brian Jakes, Jr. | Dr. Fred Pescatore | Dr. Tom Burke, Ph.D | Eric S. Freedland | Evan D. Rosen | Ginger Kanzer-Lewis | Greg Milliger | Kristina Sandstedt | Laura Plunkett | Leonard Lipson, M.A. | Louis H. Philipson | Maria Emanuel Ryan, DDS, PhD | Marilyn Porter, RD, CDE | Melissa Diane Smith | Michael R. Cohen, RPh, MS, ScD, FASHP | Paul Chous, M.A., OD | Philip A. Wood PhD | R. Keith Campbell, Professor, B.Pharm, MBA, CDE | Richard K. Bernstein, MD | Sheri R. Colberg PhD | Sherri Shafer | Stanley Schwartz, MD, FACP, FACE | Steve Pohlit | Steven V. Edelman, M.D. | Timothy S. Hollingshead |

Cast Your Vote
Have you recommended the use of an SGLT-2 inhibitor to any of your type 1 patients?

CME/CE of the Week
Vickie Driver, DPM, MS, FACFAS

Category: Wound Care
Credits: 1.0